Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

August 11, 2015

Primary Completion Date

April 24, 2017

Study Completion Date

April 23, 2018

Conditions
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Interventions
DRUG

dimethyl fumarate

Initial oral dose for 7 days with maintenance dose thereafter

Trial Locations (34)

1113

Research Site, Sofia

1606

Research Site, Sofia

2930

Research Site, Brasschaat

5800

Research Site, Plaven

Research Site, Pleven

7100

Research Site, La Louvière

8000

Research Site, Bruges

27607

Research Site, Raleigh

29307

Research Site, Spartanburg

30342

Research Site, Atlanta

33609

Research Site, Tampa

33612

Research Site, Tampa

Research Site, Baltimore

34471

Research Site, Ocala

34677

Research Site, Oldsmar

41380

Research Site, Umuttepe

49684

Research Site, Traverse City

66212

Research Site, Overland Park

78258

Research Site, San Antonio

84103

Research Site, Salt Lake City

85234

Research Site, Gilbert

90806

Research Site, Long Beach

92288

Research Site, Klaipėda

98405

Research Site, Tacoma

Unknown

Research Site, Sofia

00001

Research Site, Kuwait City

LT-50009

Research Site, Kaunas

LT-08661

Research Site, Vilnius

85-795

Research Site, Bydgoszcz

40-595

Research Site, Katowice

40-650

Research Site, Katowice

90-324

Research Site, Lodz

62-064

Research Site, Plewiska

70-215

Research Site, Szczecin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY